Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Up 6.13%
As of Friday, August 21, Lexeo Therapeutics, Inc.’s LXEO share price has surged by 6.13%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Commentary & Analysis
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Up 6.80%
As of Wednesday, August 19, Lexeo Therapeutics, Inc.’s LXEO share price has surged by 6.80%, which has investors questioning if this is right time to sell.Michael Rose
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%
As of Friday, July 31, Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.15%
As of Friday, July 10, Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.87%
As of Thursday, July 09, Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 5.87%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | LXEO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $403.6 | $285.0 | 34% |
|
| Shares Out (Mil) | 85.6 | 53.9 | 59% |
|
| Institutional Ownership | 99.5% | 93.2% | 89% |
|
| Float (Mil) | 50.3 | 41.4 | 47% |
|
| Beta | 1.47 | 0.95 | 82% |
|
| Avg Daily Volume (000s) | 940 | 523 | 70% |
|
| Price Change (52-week) |
2.9% | 58.8% | 47% |
|
| Growth | LXEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (80.6%) | (10.1%) | 3% |
|
| EPS (5yr) | 12.2% | 15.8% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (51.9%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.323) | ($1.199) | ($1.369) | |
| Month Ago EPS | ($0.301) | ($1.139) | ($1.243) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.297) | ($1.135) | ($1.224) | |
| Year/Year Chg | 7.0% | (35.6%) | (29.6%) | |
| Financials | LXEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($87) | ($43) | 12% |
|
| EPS (TTM) | ($1.146) | ($1.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $57 | $2 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $195 | $186 | 26% |
|
| Valuation | LXEO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.65 | 2.85 | 42% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LXEO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (40.5%) | (47.3%) | 14% |
|
| ROE | (46.8%) | (55.1%) | 16% |
|
| Liabilities to Assets | 7.8% | 29.6% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 8/24/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
